USPTO serial 79363770
RESEARCH PIECES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 28, 2026
- Examiner
- DERBY, KAREN SHEREE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RESEARCH PIECES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michelle P. Ciotola
Michelle P. Ciotola Cantor Colburn LLP20 Church Street22nd FloorHartford, CT 06103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological, biochemical and chemical preparations for use in industry, science and for scientific purposes other than for medical or veterinary use; biological preparations for use in cell cultures other than for medical or veterinary use; stem cells for research purposes; stem cells for science, for scientific purposes; biological microorganisms other than for medical or veterinary use; cultures of microorganisms other than for medical or veterinary use ; cultures of microorganisms and cell media cultures other than for medical or veterinary use; biological tissue from different organs, namely from rodent, primate and human biopsy and cell media cultures, other than for medical or veterinary use; cultures of microorganisms for industrial use, other than for medical or veterinary use; cell culture media for laboratory use; cell culture media for use in non-medical research laboratories and in the biotechnology industry; cell growth media for cell culture for use in scientific research; solutions for non-medical scientific use for storing and preserving human organs; chemical compositions for scientific and industrial use for the preparation of culture media; biochemicals for in-vitro and in-vivo scientific use; chemical for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; chemical laboratory preparations for scientific purposes, other than for medical or veterinary use ; preservatives for the viability of micro-organisms in cultures for pharmaceutical industrial use; biological preparations other than for medical and veterinary use; bacterial preparations for scientific and industrial use; chemical preparations for analyses in laboratories, other than for medical or veterinary use; chemical preparations for pathological examinations, other than for medical and veterinary use; chemical preparations, biochemical preparations, reagents, chemical reagents and diagnostic preparations for scientific or research use other than for medical or veterinary use; diagnostic reagents for in-vitro use other than for medical use, in vivo for scientific use, in-vitro use for biochemistry, clinical chemistry and microbiology; reagents for in-vitro use in laboratories other than for medical or veterinary use; cell culture reagents for scientific use and for research; reagents for chemical and microbiological analysis other than for medical or veterinary use; test reagents for scientific or industrial use other than medical use; chemical reagents for use in scientific field, for molecular biology and for biotechnology other than for medical or veterinary use; chemical preparations used for analysis, reagents for analytical tests and diagnostic tests for biological treatment other than for medical or veterinary use | ACTIVE | — |
| 005 | Biological, chemical, biochemical preparations, antibodies, antiviral substances, antibiotics, anticancer substances, agents, molecules, reagents for medical and pharmaceutical use for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders, or cancer; chemical and biochemical products for pharmaceutical use for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; chemico-pharmaceutical products for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical products for the prevention and treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical products, agents or molecules targeting neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical products for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer for use in organ transplant; organotherapy preparations; chemical and biological reagents for medical use for analyses for medical use; reagents for in vitro use in laboratories for medical use; reagents for use in genetic testing and medical diagnostic testing; diagnostic chemical reagents for medical use; reagents for chemical and microbiological analyses for medical use; immunological reagents for medical use; biological preparations from tissues, organs, biochemical, biotechnological and chemical preparations for medical use for analyses and treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; chemical preparations for medical use for blood analysis of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; preparations of micro-organisms for medical use for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; chemical-pharmaceutical preparations for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations and substances for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations for tissue regeneration for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations containing stem cells for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations for human use for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical preparations for activating cellular function for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; diagnostic in vitro preparation for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; living cells for medical use; stem cells for medical use; stem cells for use in cell and gene therapies for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; culture media for biological tissue grafts or implants comprising living tissue; bacteriological culture media and culture media for bacteriology for medical use; cell growth media for growing cells for medical use; cell culture media for biological tissue grafts, implants comprising living tissue; cultures for biological tissue grafts, implants comprising living tissue and stem cell therapy; biological tissue cultures for medical use; cultures of micro-organisms for grafts, implants and stem cells in neurodegenerative, inflammatory, infectious and viral diseases, immune and metabolic disorders or cancer; blood for medical purposes; surgical implants comprised of living tissues obtained from stem cells; biological neural, skin tissues for implantation and transplantation; grafts in the nature of skin grafts, arterial grafts, and biotechnical tissue grafts; arterial grafts; vascular grafts in the nature of living tissue; skin grafts; biological implants and implants, namely cells culture, stem cells, tissues for pharmaceutical use; implants comprising living tissues for guided tissue regeneration; surgical implants comprised of living tissues, grown from stem cells; human tissue for allografts; processed human donor skin for the replacement of soft tissue and biological tissue culture for medical use; human growth hormones; vaccines for human use; viral vaccines | ACTIVE | — |
| 042 | Scientific, technological and biotechnological services, namely analysis, tests, design, advices and studies in the field of neurosciences, cancer, genetics, epigenetics, microbiology and viruses; pharmaceutical product evaluation in the nature of conducting scientific studies and tests on pharmaceutical products; scientific laboratory services; biological and medical research laboratory services; chemical research laboratory services; pharmaceutical research and development services in the field of cytology, chemistry, gene expression systems, engineering, biotechnology, physics and medical field; pharmaceutical research and development services in the field of vaccines; pharmaceutical product development services; scientific research services for medical purposes concerning all pathologies; biochemical research services; drug discovery services; DNA screening services for scientific research; biological cloning services; biochemical engineering; chemical engineering; genetic engineering services in the nature of advisory and technical consulting in the fields of neurosciences, cancer, genetics, epigenetics, microbiology and viruses; microbiological testing services in the nature of fluids analysis, blood analysis, cerebrospinal fluid analysis, urine analysis; scientific research services with respect to the isolation and cultivation of human cells, and of tissues; biotechnology product testing, technical product testing and pharmaceutical product testing services; product testing in the nature of services for assessing the efficiency of pharmaceutical products and industrial chemicals; blood analysis services for scientific research purposes; providing information relating to scientific research; consulting services in the fields of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine research; advisory services and technical consulting in the fields of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine research; advisory services with respect to gene therapy research; advisory services with respect to research and development in the field of therapeutics and biotechnology; advisory services in engineering and with respect to biochemistry; advisory services with respect to scientific laboratory services; consulting services in the field of pharmaceutical research and development; consulting services in the field of information technology for the pharmaceutical and health industries; consulting services in the field of biology and pharmaceutical research and development; medical, biomedical, pharmaceutical and pharmacological research services; chemical research and analysis services; laboratory research services relating to pharmaceutical products; laboratory research in the field of biotechnology and chemistry; biological research; pharmaceutical research services; technology research in the field of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine; biotechnology research; research in the field of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine; research in the field of chemistry; research in the field of biochemistry; scientific research in the field of genetics; scientific research in the field of molecular science, genetic engineering, gene therapy, pharmaceuticals and pharmacogenetics; scientific research for medical purposes concerning all pathologies; biological and medical research; clinical research in the field of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine; biological and biochemical research and analysis; research and development of products, new products, vaccines and medicines; scientific, biotechnological, biochemical research and development for the pharmaceutical industry; research and development in the field of diagnostic preparations; development of pharmaceutical preparations, products and medicines; scientific research in the field of cell culture; scientific research in the field of stem cells; research and development in the field of stem cells; research services in the field of neurosciences, cancer, genetic, epigenetics, microbiology and viruses, namely, biological sample preparations for research purposes, for testing and analysis in research laboratories; tissue engineering; cultivation and engineering of cells and tissues for scientific and research purposes, for others; analysis in the field of molecular biology and technology engineering; medical research in the nature of analyses on human tissues and human serums; scientific research in the field of neurosciences, cancer, genetic, epigenetics, microbiology, viruses and vaccine, conducted using databases; medical research conducted using databases; technology research in the field of neurosciences, cancer, genetic, epigenetics, microbiology and viruses provided by engineers testing new products, chemical products, engineering, toxicity for research purposes; genetic testing on laboratory animals for research purposes; design and testing in the framework of new product development; designing and developing engineering products; conducting engineering studies in the nature of preclinical molecules screening, clinical trials, vaccine engineering studies, therapeutics engineering studies, genetics in the field of biochemistry and biotechnology; preparation of reports with respect to biotechnology; providing information relating to medical and scientific research information in the field of pharmaceuticals, clinical trials and scientific technology; providing information relating to scientific research and information services with respect to technological research; providing information relating to scientific research in the field of biochemistry and biotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by RESEARCH PIECES
- Other trademarks owned by RESEARCH PIECES
- Other trademarks owned by RESEARCH PIECES
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named RESEARCH PIECES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 30, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 28, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 28, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 28, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 10, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 10, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 5, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 18, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 17, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 10, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 8, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 8, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 8, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 11, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jul 22, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 21, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 3, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 3, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 3, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 29, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 29, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 28, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 27, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 26, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 3, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 27, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |